The prognostic value of pain in castration-sensitive prostate cancer-Reference-Cited by-同舟云学术

The prognostic value of pain in castration-sensitive prostate cancer

Published:2020-07-10 Issue:4 Volume:23 Page:654-660
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Iacovelli Roberto^ORCID,Ciccarese Chiara,Caffo Orazio^ORCID,De Giorgi Ugo,Tucci Marcello,Mosillo Claudia,Bimbatti Davide,Pierantoni Francesco,Maines Francesca,Casadei Chiara^ORCID,Buttigliero Consuelo,Milella Michele,Tortora Giampaolo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-020-0255-x.pdf

Reference20 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

2. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016;19:395–7.

3. Iacovelli R, Ciccarese C, Mosillo C, Bimbatti D, Fantinel E, Stefani L, et al. Comparison between prognostic classifications in de novo metastatic hormone sensitive prostate cancer. Target Oncol. 2018;13:649–55.

4. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl J Med. 2015;373:737–46.

5. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163–77.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED);European Urology Oncology;2024-04

2. Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives;Cancer Treatment Reviews;2024-03

3. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis;Clinical Genitourinary Cancer;2023-09

4. Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with²²³Ra: PARABO, a Prospective, Noninterventional Study;Journal of Nuclear Medicine;2023-06-29

5. Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer—exploratory analysis of LATITUDE study;Prostate Cancer and Prostatic Diseases;2022-09-13